Crossmark Global Holdings’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Crossmark Global Holdings’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,062	Closed	-$206K	–	1332
2023 Q2	$206K	Buy	2,062 +38	+2%	+$4.01K	﹤0.01%	1244
2023 Q1	$221K	Buy	2,024 +191	+10%	+$21.1K	0.01%	1182
2022 Q4	$209K	Buy	+1,833	New	+$152K	0.01%	1185
2022 Q2	–	Sell	-2,135	Closed	-$225K	–	1364
2022 Q1	$225K	Buy	+2,135	New	+$208K	0.01%	1258
2021 Q4	–	Sell	-7,315	Closed	-$801K	–	1502
2021 Q3	$801K	Buy	+7,315	New	+$759K	0.02%	689

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Crossmark Global Holdings's HZNP Position: Q3 2023 in Review

Crossmark Global Holdings sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 2,062 shares — an estimated $206K sold.

Crossmark Global Holdings first reported a position in HZNP in Q3 2021 and held it in 5 quarters. The position peaked at $801K in Q3 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Crossmark Global Holdings reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Crossmark Global Holdings sold 2,062 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $206K.
Crossmark Global Holdings first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 5 quarters.
Crossmark Global Holdings's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $801K in Q3 2021.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Crossmark Global Holdings's 13F filing for Q3 2023, filed 8 Nov 2023.